Biophysical methods to study the binding of oritavancin, a lipoglycopeptide, to serum protein are confounded by nonspecific drug adsorption to labware surfaces. We assessed oritavancin binding to serum from mouse, rat, dog, and human by a microbiological growth-based method under conditions that allow near-quantitative drug recovery. Protein binding was similar across species, ranging from 81.9% in human serum to 87.1% in dog serum. These estimates support the translation of oritavancin exposure from nonclinical studies to humans.
机构:
Hartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, JapanHartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
Crandon, Jared
Nicolau, David P.
论文数: 0引用数: 0
h-index: 0
机构:
Hartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USAHartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
机构:
Hartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, JapanHartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
Crandon, Jared
Nicolau, David P.
论文数: 0引用数: 0
h-index: 0
机构:
Hartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USAHartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan